Wockhardt launches generic midazolam injections in the US
This article was originally published in Scrip
Wockhardt has launched preservative-free midazolam injections 1mg/ml and 5mg/ml in the US. The product is a generic version of Roche's Versed for acute insomnia and anxiety and represents Wockhardt's fourth injection ANDA approval in the past two months and the twelfth sterile product to be approved in the US. Wockhardt now has FDA approval for both preservative-free injections containing midazolam, and midazolam injections containing preservatives. The injections are manufactured at Wockhardt's US FDA-certified formulation plant in Waluj. The US market for midazolam injections is estimated at $56 million.
You may also be interested in...
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
A senior executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world. While the company has prior experience with the "deep frozen" temperatures needed for some candidates, there will still be specific challenges and complexities involved.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.